The Neuro Experience

The New Science That’s Changing Everything We Know About Obesity | ft. Dr. Rocio Salas-Whalen

Oct 16, 2025
In this engaging discussion, Dr. Rocio Salas-Whalen, an obesity and metabolic health specialist, dives into the complexities of GLP-1 medications. She explains how these drugs go beyond weight loss, highlighting their roles in reducing cancer and Alzheimer’s risk through anti-inflammatory properties. Dr. Salas-Whalen also discusses how menopause affects fat gain and the potential of combining hormone replacement therapy with GLP-1s. Plus, she debunks myths around willpower and obesity, emphasizing the genetic factors at play.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

GLP-1s Are Rapidly Evolving Therapeutics

  • GLP-1 drugs are evolving like iPhones with newer versions combining hormones for greater efficacy.
  • Triple agonists (GLP-1, GIP, glucagon) show phase‑3 results with far larger weight loss than earlier drugs.
INSIGHT

Glucagon May Boost Weight Loss — Mechanism Unknown

  • Adding glucagon to GLP-1 and GIP produced much larger weight loss in trials, though the mechanism is unclear.
  • Researchers observed up to ~40% body weight loss versus ~24% with dual agonists in early results.
INSIGHT

Estrogen Loss Drives Midlife Fat Shift

  • After age 40 women commonly gain 1–2 pounds per year largely due to changing estrogen.
  • Estrogen protects against visceral, pro‑inflammatory fat and its decline shifts fat centrally increasing metabolic risk.
Get the Snipd Podcast app to discover more snips from this episode
Get the app